XML 23 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating activities    
Net loss $ (40,116) $ (144,666)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 3,671 1,782
Equity-based compensation 26,501 1,675
Change in fair value of warranty liability (24,675) 84,317
Realized and unrealized gain on marketable securities (72)
Fixed asset write-off 96
Issuance of warrants for rent expense 9,033
Equity method investment income (loss) 230
Asset retirement obligation accretion 56 236
Amortization of debt issuance costs and discount 9,257
Accrued payment in kind (“PIK”) interest on debt 4,714
Changes in operating assets and liabilities:    
Accounts receivables (428) (1,663)
Other current assets 593 (3,634)
Other assets 161 (879)
Accounts payable 486 (7,020)
Deferred revenue (1,537) 1,632
Accrued expenses and other liabilities (2,501) (2,812)
Operating lease right-of-use assets and liabilities 536
Net cash used in operating activities (37,095) (47,932)
Investing activities    
Capitalization of costs and purchases of network assets, property, and equipment (2,964) (1,022)
Purchase of equity method investments (1,125)
Purchase of marketable securities (13,644)
Sale and maturity of marketable securities 5,500
Purchase of business, net of cash acquired (2,890)
Purchase of internal use software (613) (260)
Net cash used in investing activities (15,736) (1,282)
Financing activities    
Proceeds from debt 24,638
Payments towards debt (17) (96,871)
Proceeds from exercise of stock option 57
Proceeds from issuance of common stock 7 2
Net cash contribution from Business Combination and PIPE financing, net of transaction and issuance costs 207,872
Purchase of common stocks (withholding taxes) (4)
Net cash provided by financing activities 43 135,641
Effect of exchange rates on cash and cash equivalents (58) (20)
Net increase (decrease) in cash and cash equivalents (52,846) 86,407
Cash and cash equivalents at beginning of period 100,076 13,669
Cash and cash equivalents at end of period 47,230 100,076
Non-cash investing and financing activities    
Common stock issued in acquisition of business 13,888
Capital expenditure included in Accounts payables 605
Recapitalization of redeemable convertible preferred units into common stock 383,430
Exercise of warrants 174,327
Reclassification of warrant liability to common stock warrants 22,194
Issuance of warrants 9,033
Interest paid $ 4,939